Ozari Health is a New York-based telehealth platform launched May 19, 2026 that prices compounded semaglutide at $86/month and compounded tirzepatide at $120/month — the lowest published price points in the US compounded-GLP-1 segment at launch. Patients complete an online intake, get evaluated by state-licensed providers, and receive prescriptions filled by partner compounding pharmacies. Hallandale Pharmacy and VialsRX are the initial pharmacy partners, with additional partners coming online. Branded Wegovy, Ozempic, Mounjaro, and Zepbound are also available through the same channel for patients who prefer branded product.
Ozari's pricing structure sits at the floor of the compounded GLP-1 telehealth market. Comparable platforms — Sesame ~$99/month, Henry Meds $129-249, Wisp ~$199, Mochi Health $129 introductory — all priced above Ozari's launch tier. The multi-pharmacy partner model distinguishes Ozari from platforms working with a single compounding partner; patients can choose pharmacy based on shipping speed, formulation preference, or insurance routing. The launch lands six weeks before the FDA's June 29 public-comment deadline on the April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — putting the long-term viability of the compounded segment under regulatory pressure.
Stories here cover Ozari pricing announcements, pharmacy-partner additions, FDA regulatory developments affecting the platform, and the broader compounded-GLP-1 competitive landscape. See #compounded-glp-1, #telehealth, and #503a-compounding for adjacent threads.
Six weeks ahead of the FDA's June 29 closing date for public comments on the April 30 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide, the compounded-GLP-1 telehealth segment has settled into a defensive pricing structure. Ozari Health's May 19 launch at $86/month compounded semaglutide and $120/month compounded tirzepatide established the floor; comparable platforms have held prices steady at $99-249/month rather than competing further on price. The Saturday market sentiment is split: bull case is that the FDA's final determination could grandfather existing 503A patients under a transition window, leaving cash-pay compounded GLP-1 viable through 2027; bear case is that the BSR Intelligence-documented 90% YoY drop in compounded semaglutide shipments accelerates as 503B compounding ends, with only the smallest-volume 503A pharmacies remaining. Patient migration toward branded Wegovy via Novo's Hims & Hers branded-distribution channel (125K shipments in six weeks) is the natural off-ramp.
Ozari Health, a New York-based telehealth company, launched a nationwide platform on Tuesday May 19, 2026 offering compounded semaglutide starting at $86/month and compounded tirzepatide starting at $120/month, with branded options (Wegovy, Ozempic, Mounjaro, Zepbound) available through the same channel. Patients complete an online intake, get evaluated by state-licensed providers, and receive prescriptions filled by partner compounding pharmacies including Hallandale Pharmacy and VialsRX — the multi-pharmacy partner structure differentiates Ozari from telehealth platforms that work with a single compounding partner. Ozari pricing sits at the floor of the compounded GLP-1 market; comparable platforms (Sesame, Henry Meds, Wisp) range $99-249/month for compounded semaglutide. The launch lands as the FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (comments closing June 29) puts long-term compounding-pharmacy access in question.
Tuesday's Ozari Health launch at $86/month for compounded semaglutide and $120/month for compounded tirzepatide places the platform at the low end of the compounded GLP-1 telehealth pricing band. Comparable platforms in the same market: Sesame ~$99/month, Henry Meds $129-249/month, Wisp ~$199/month, Mochi Health $129/month introductory, MD Lifestyle $99-249/month. The pricing-floor compression is colliding with the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — comments close June 29, with the final determination expected late Q3 2026. If the FDA's 503B proposal stands, large-scale 503B compounding ends and platforms either shift to 503A pharmacies (lower volume, higher unit cost) or wind down. The current cohort of telehealth launches at $86-129/month likely represents the cheapest US compounded GLP-1 will be before the regulatory regime tightens. Branded Wegovy and Foundayo's $25-149/month commercial-insurance copays remain the lower-cost path for insured patients; the cash-pay compounded market is what these telehealth launches are competing for.